Therapies that target the actions of CGRP have been shown to be effective in preventing migraine – including small molecule antagonists (gepants), and antibody therapies targeting CGRP or its receptor.[Karsan & Goadsby, 2015]
A systematic review collected data from high-quality RCTs assaying the efficacy and safety of anti-CGRP antibody therapies for the preventative treatment of episodic migraine.[Deng et al., 2020] . A smaller review of gepants for prevention of migraine concluded that the investigated gepants were effective and safe for the prevention of migraine[Dos Santos & Da Silva, 2022]. All the anti-CGRP treatments are relatively new; consequently, real-world data and data on long-term effects are needed.
Other reference used on slide:
Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695-706.
European Medicines Agency, Medicines. https://www.ema.europa.eu/en/medicines/human/EPAR/vydura. Accessed Oct 2022
Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drugs: atogepant. htt ps://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215206Orig1s000lbl. pdf. (Accessed 21 September 2022).
Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drugs: rimegepant. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s012lbl.pdf. (Accessed 21 September 2022).